托伐普坦片在国内能买到了吗?

The Indian version of Tolvaptan tablets (Tolvaptan) is a generic version, and the purchase situation in China is not clear, because the Indian version of Tolvaptan tablets is not on the market in mainland China. At present, we know how to buy Tolvaptan tablets. The formula includes formal sales places such as regular pharmacies, hospitals, clinics, retail pharmacies and online pharmacies, as follows:

1. Hospital pharmacies:

Tolvaptan tablets can be purchased in hospital pharmacies, especially those hospitals that can provide close monitoring of patients' serum sodium levels.

2. Online pharmacies:

Some legal online pharmacies may offer tolvaptan tablets for sale, such as Haiou Pharmacy.com. When purchasing, patients should ensure the legitimacy of the pharmacy and the authenticity of the medicine.

3. Physical pharmacies:

Tolvaptan tablets may also be sold in some large chain pharmacies or independent pharmacies.

4. Drug agents:

Sometimes, drug agents will also provide sales services for tolvaptan tablets.

5. Purchase on pharmaceutical e-commerce platforms:

In China, some pharmaceutical e-commerce platforms also provide sales services for tolvaptan. However, patients need to pay attention to choosing a qualified drug website and ensure that the drugs purchased have legal registration certificates.

6. Overseas medical service institutions:

Look for professional and qualified overseas medical service institutions online. They may cooperate with pharmacies at home and abroad and can help patients obtain medicines, which are guaranteed to be genuine and delivered to their homes.

Effects of Tolvaptan Tablets

Tolvaptan is the first orally active, specific V2 receptor antagonist licensed for human use. It counteracts the effects of vasopressin by blocking V2 receptors, thereby reducing the expression of aquaporin channels.

The safety and efficacy of tolvaptan have been studied in two of the largest clinical trials in patients with ADPKD (autosomal dominant polycystic kidney disease): TEMPO3:4 and REPRISE. Both showed reduced renal function decline compared with placebo.

The TEMPO 3:4 study found that total kidney volume decreased by an average of 49% from baseline to post-treatment. TEMPO 3:4 is a randomized clinical trial in patients aged 18 to 50 years with ADPKD. Participants (n = 1445) with total renal volume >750 mL and creatinine clearance >60 mL/min were randomly assigned to receive placebo or tolvaptan for 3 years.

Tolvaptan is administered in doses of 45 mg in the morning and 15 mg in the afternoon, with subsequent dose escalations. The primary outcome was the percent change in total kidney volume. Changes in total renal volume were 9.6% and 18.8% in the placebo and placebo groups, respectively. Patients treated with tolvaptan had fewer episodes of renal pain and a lower rate of worsening of renal function, as measured by increases in serum creatinine and changes in eGFR.

After treatment with tolvaptan, the mean increase in serum creatinine was 0.16 mg/dl compared with 0.23 mg/dl in the placebo group. The annual eGFR slope change was -2.72 mL/min/1.73 m 2 in the tolvaptan group and -3.70 mL/min/1.73 m 2 in the placebo group. Proteinuria was also significantly reduced in patients treated with tolvaptan.

TEMPO 4:4 studied the long-term effects of tolvaptan by following 871 patients who completed TEMPO 3:4. Over the next 24 months, patients received doses of 45, 60, or 90 mg in the morning and 15 or 30 mg 9 hours later.

After 24 months, the change in total renal volume from TEMPO 3:4 to TEMPO 4:4 was 29.9% and 31.6% in patients receiving tolvaptan and placebo, respectively.

The change in eGFR during early treatment during TEMPO 4:4 was -3.26% per year, the change in eGFR per year during delayed treatment was -3.14%, and there was no significant change in eGFR after long-term tolvaptan treatment. Tolvaptan treatment can effectively slow down the increase in total renal volume and correct renal function in the short term.

Tolvaptan tablets specifically antagonize arginine vasopressin and are used to treat hypervolemic or isovolemic hyponatremia associated with heart failure, cirrhosis, and syndrome of abnormal secretion of antidiuretic hormone. It is recommended that patients take medication under the guidance of a doctor, treat symptoms, and not use it blindly.

Recommended hot articles: